This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (23)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Articles for Residents  • Ophthalmology, Other  • Alert me on articles by topic

Shelley R. Boyd, MD; Ian Zachary, PhD; Usha Chakravarthy, FRCS; George J. Allen, PhD; G. Brian Wisdom, PhD; Ian A. Cree, PhD; John F. Martin, MD; Philip G. Hykin, FRCS

Arch Ophthalmol. 2002;120:1644-1650.

Objective  To establish a role for vascular endothelial growth factor (VEGF) during the onset and clinical course of neovascularization of the iris (NVI) in ischemic central retinal vein occlusion.

Methods  Sixteen patients with ischemic central retinal vein occlusion were followed up for 12 months by clinical examination, retinal and iris angiography, and serial anterior chamber sampling of aqueous humor. Aqueous VEGF level was determined by enzyme-linked immunoassay, and permeability changes were estimated by capillary zone electrophoretic assessment of aqueous albumin.

Results  A correlation was found between aqueous VEGF concentrations and the onset, persistence, and regression of NVI; extent of retinal capillary nonperfusion; and vascular permeability. The NVI occurred when aqueous VEGF concentrations were 849 to 1569 pg/mL and regressed fully when they fell below 550 pg/mL. Aqueous concentrations of serum albumin, a marker of increased permeability, correlated with increased VEGF. Placental growth factor was found at low levels only when VEGF levels exceeded 330 pg/mL. The NVI remained VEGF-dependent during the course of the disease, regressing only if VEGF concentrations were reduced after laser ablation of hypoxic retina.

Conclusions  The close temporal correlation between aqueous VEGF levels and the course of neovascularization and permeability in human ischemic central retinal vein occlusion indicates that increased aqueous VEGF level may predict the need for treatment, and that anti-VEGF therapy at an early stage of ischemic central retinal vein occlusion may be therapeutically beneficial.

From the Moorfields Eye Hospital, London, England (Drs Boyd and Hykin); Centre for Cardiovascular Biology and Medicine, Department of Medicine, The Rayne Institute, University College London, London (Drs Zachary and Martin); Ophthalmology and Vision Science, Queens University Hospitals, Belfast, Northern Ireland (Dr Chakravarthy); School of Biology and Biochemistry, Queen's University Belfast, Belfast (Drs Allen and Wisdom); and Department of Pathology, Institute of Ophthalmology, London (Drs Boyd and Cree).

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Intravitreal Avastin for macular oedema secondary to retinal vein occlusion: a prospective study
Kriechbaum et al.
Br. J. Ophthalmol. 2008;92:518-522.
ABSTRACT | FULL TEXT  

Intravitreal bevacizumab for the treatment of macular oedema secondary to branch retinal vein occlusion
Kreutzer et al.
Br. J. Ophthalmol. 2008;92:351-355.
ABSTRACT | FULL TEXT  

Vascular endothelial growth factor biology: clinical implications for ocular treatments.
Bhisitkul
Br. J. Ophthalmol. 2006;90:1542-1547.
ABSTRACT | FULL TEXT  

Hepatocyte Growth Factor Induces Retinal Vascular Permeability via MAP-Kinase and PI-3 Kinase without Altering Retinal Hemodynamics.
Clermont et al.
IOVS 2006;47:2701-2708.
ABSTRACT | FULL TEXT  

The Role of Adult Bone Marrow-Derived Stem Cells in Choroidal Neovascularization
Sengupta et al.
IOVS 2003;44:4908-4913.
ABSTRACT | FULL TEXT